Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Sarcoma × ARQ 197 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 9 Carcinoma, Non-Small-Cell Lung 3 Solid Tumors 2 Carcinoma, Hepatocellular 2 Solid Neoplasm 1 Sarcoma 1 Neoplasm Metastasis 1 Melanoma 1 Fibrosis 1 Childhood Solid Neoplasm 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Adult Solid Neoplasm 1

Interventions

Doxorubicin 24 Cyclophosphamide 24 Gemcitabine 14 Radiotherapy 12 Filgrastim 11 pazopanib 10 pembrolizumab 9 Cisplatin 9 Docetaxel 8 Radiation 7 Ifosfamide 7 Granulocyte Colony-Stimulating Factor 7 Carboplatin 7 Busulfan 7 fludarabine 6 Trabectedin 6 Peripheral Blood Stem Cell Transplantation 6 Mesna 6 Melphalan 6 Ipilimumab 6 Etoposide 6 Bevacizumab 6 selinexor 5 olaratumab 5 Temozolomide 5 Leucovorin 5 Irinotecan 5 aflibercept 4 Topotecan 4 Thiotepa 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01468922 2022-07-01

Pazopanib and ARQ 197 for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

32 enrolled 21 charts

Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡